Dendritic cell vaccination in pediatric gliomas: lessons learnt and future perspectives

Immunotherapy of malignant gliomas with autologous dendritic cells (DCs) in addition to surgery and radiochemotherapy has been a focus of intense research during the past decade. Since both children and adults are affected by this highly aggressive brain tumor, 10-15% of the several hundred vaccinat...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in pediatrics Vol. 1; p. 12
Main Authors Eyrich, Matthias, Rachor, Johannes, Schreiber, Susanne C, Wölfl, Matthias, Schlegel, Paul G
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 10.06.2013
Subjects
Clinical Trial
DC vaccination
Immunotherapy
malignant glioma
Pediatrics
clinical trial
malignant glioma
DC vaccination
immunotherapy
pediatrics
Online AccessGet full text

Cover

More Information
Summary:Immunotherapy of malignant gliomas with autologous dendritic cells (DCs) in addition to surgery and radiochemotherapy has been a focus of intense research during the past decade. Since both children and adults are affected by this highly aggressive brain tumor, 10-15% of the several hundred vaccinated patients represent children, making pediatric glioma patients the largest uniform pediatric vaccination cohort so far. In general, DC vaccination in malignant gliomas has been shown to be safe and several studies with a non-vaccinated control group could clearly demonstrate a survival benefit for the vaccinated patients. Interestingly, children and adolescents below 21 years of age seem to benefit even more than adult patients. This review summarizes the findings of the 25 clinical trials published so far and gives a perspective how DC vaccination could be implemented as part of multimodal therapeutic strategies in the near future.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
This article was submitted to Frontiers in Pediatric Oncology, a specialty of Frontiers in Pediatrics.
Edited by: Peter Bader, University Hospital for Childhood and Adolescence Medicine, Germany
Reviewed by: Tobias Feuchtinger, University Children’s Hospital, Germany; Ettore Biagi, University of Milano-Bicocca, Italy
ISSN:2296-2360
2296-2360
DOI:10.3389/fped.2013.00012